| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13G · 3 securities · passive | ||||||
|
DBV Technologies S.A.
13G/A
DBVT · 23306J309
|
0% |
2/17/2026
Event 12/31/2025
|
||||
| Venrock Healthcare Capital Partners II, L.P. | 0% | |||||
| VHCP Co-Investment Holdings II, LLC | 0% | |||||
| VHCP Management II, LLC | 0% | |||||
| Venrock Healthcare Capital Partners III, L.P. | 0% | |||||
| VHCP Co-Investment Holdings III, LLC | 0% | |||||
| Venrock Healthcare Capital Partners EG, L.P. | 0% | |||||
| VHCP Management III, LLC | 0% | |||||
| VHCP Management EG, LLC | 0% | |||||
| Nimish Shah | 0% | |||||
| Bong Y. Koh | 0% | |||||
|
Cogent Biosciences, Inc.
13G/A
COGT · 19240Q201
|
4.2% |
8/14/2025
Event 6/30/2025
|
||||
| Venrock Healthcare Capital Partners II, L.P. | 4.2% | |||||
| VHCP Co-Investment Holdings II, LLC | 4.2% | |||||
| VHCP Management II, LLC | 4.2% | |||||
| Venrock Healthcare Capital Partners III, L.P. | 4.2% | |||||
| VHCP Co-Investment Holdings III, LLC | 4.2% | |||||
| Venrock Healthcare Capital Partners EG, L.P. | 4.2% | |||||
| VHCP Management III, LLC | 4.2% | |||||
| VHCP Management EG, LLC | 4.2% | |||||
| Nimish Shah | 4.2% | |||||
| Bong Y. Koh | 4.2% | |||||
|
Trevi Therapeutics, Inc.
13G/A
TRVI · 89532M101
|
1.4% |
2/14/2025
Event 12/31/2024
|
||||
| Venrock Healthcare Capital Partners II, L.P. | 1.4% | |||||
| VHCP Co-Investment Holdings II, LLC | 1.4% | |||||
| VHCP Management II, LLC | 1.4% | |||||
| Venrock Healthcare Capital Partners III, L.P. | 1.4% | |||||
| VHCP Co-Investment Holdings III, LLC | 1.4% | |||||
| Venrock Healthcare Capital Partners EG, L.P. | 1.4% | |||||
| VHCP Management III, LLC | 1.4% | |||||
| VHCP Management EG, LLC | 1.4% | |||||
| Nimish Shah | 1.4% | |||||
| Bong Y Koh | 1.4% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.